Grail is set to start a new trial next year to assess the ability of an investigational blood test to detect a number of cancer types.
SUMMIT is a prospective observational, longitudinal, cohort study that aims to enrol around 50,000 men and women aged 50 to 77 years who do not have a cancer diagnosis at the time of recruitment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nearly half of participants will be at high risk of developing lung and other cancers because of their significant smoking history.
Healthcare company Grail is expected to use next-generation sequencing (NGS) technology as part of the trial.
It plans to carry out the trial in the UK in collaboration with University College London (UCL) and the university’s National Health Service (NHS) Foundation Trust (UCLH).
US-based non-profit organisation Lung Cancer Alliance (LCA) will provide guidance on the study design of SUMMIT.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGrail Clinical Development vice-president Anne-Renee Hartman said: “The SUMMIT study will support the development of our blood test for the early detection of multiple cancer types in a diverse population.”
SUMMIT aims to help UCL and UCLH achieve their goal of evaluating the feasibility of implementing lung cancer screening in the UK.
Participants are also expected to have the opportunity to undergo lung cancer screening with low dose computed tomography (LDCT) and will have support for smoking cessation through the NHS in the UK.
LDCT is recommended by the US Preventive Services Task Force (USPSTF) for use in people who are at high risk for lung cancer due to current or former smoking habit.
